Zhe Jiang Dayang Biotech Group (003017) Fair Value & Analysis
Basic Materials · CN · Market cap 2.3B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 19 days ago
Share price −1.2% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥15.16 (bear) to ¥25.26 (bull), base ¥20.21. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 64/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥12.58 – ¥36.20 · fair‑value band ¥15.16 – ¥25.26 · the ¥22.09 price screens above the ¥20.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Zhe Jiang Dayang Biotech Group (003017) currently trades at ¥22.09, while our model-based Fair Value estimate is ¥20.21, implying the stock looks roughly 8.5% fairly valued today. The Quality Score stands at 64/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhe Jiang Dayang Biotech Group generated revenue of 1.1B CNY at a net margin of 9.4%. Revenue grew 11.7% year over year. It earns a return on equity of 9.0%. Net debt stands at 4.1M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥15.16 (bear case) to ¥25.26 (bull case); at ¥22.09, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at -9%, 003017 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥25.45) versus Asset-Based (¥9.03). Highest evidence: Growth DCF (80).
Notify me when 003017 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally.
Full company description
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluorobenzaldehyde, and fluorobenzyl chloride. In addition, it offers aminopropionate hydrochloride; enramycin premix; and aniline. Further, it engages in the wholesale and retail of pharmaceutical intermediates; and research and development of industrial enzyme preparations and biological feeds. The company was founded in 1976 and is based in Jiande, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhe Jiang Dayang Biotech Group reported revenue of ¥1.0B in FY2025 versus ¥783M in FY2021, a compound +7.5%/yr. Reported net income was ¥99.9M in FY2025, compounding +9.3%/yr from FY2021.
Watch 003017: get an alert when its fair value changes →
Peer Group
Chemicals · 333 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BASF SE BASN | 1,034 MXN | 532.13 MXN | -49% |
| Ningxia Baofeng Energy Group 600989 | ¥20.32 | ¥20.17 | -1% |
| Zhejiang Juhua Co 600160 | ¥42.85 | ¥23.35 | -46% |
| PT Barito Pacific Tbk, BRPT | 1,690 IDR | 1,628 IDR | -4% |
| LG Chem, Ltd 051910 | 260,500 KRW | 587,755 KRW | +126% |
| Formosa Chemicals & Fibre Corporation 1326 | 66.10 TWD | 6.79 TWD | -90% |
| PTT Global Chemical Public Company PTTGC | 35.50 THB | 18.21 THB | -49% |
| 542812 542812 | ₹4,369 | ₹791.05 | -82% |
| Indorama Ventures Public Company IVL | 24.50 THB | 17.95 THB | -27% |
| Navin Fluorine International Limited NAVINFLUOR | ₹8,650 | ₹2,146 | -75% |
Compare Zhe Jiang Dayang Biotech Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Zhe Jiang Dayang Biotech Group (003017) overvalued or undervalued?
What is the fair value of 003017?
What is the quality score of 003017?
What is the revenue of Zhe Jiang Dayang Biotech Group (003017)?
What is the net profit margin of 003017?
Does Zhe Jiang Dayang Biotech Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhe Jiang Dayang Biotech Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.